GENE Profile
Genetic Technologies Limited, headquartered in Fitzroy, Australia, operates as a molecular diagnostics company specializing in predictive genetic testing and risk assessment tools. The company serves a global clientele, spanning the United States, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific regions. It operates through two main segments: EasyDNA and GeneType/Corporate.
Within its portfolio, Genetic Technologies offers BREVAGenplus, a clinically validated risk assessment test designed specifically for non-hereditary breast cancer. This test is marketed extensively to healthcare professionals in breast health care and imaging centers, as well as to specialists such as obstetricians/gynecologists and breast cancer risk assessment experts, including breast surgeons.
Additionally, Genetic Technologies provides a range of cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brands. The company continues to innovate in the field of genetic diagnostics, developing new risk assessment tests across various diseases including colorectal cancer, ovarian cancer, prostate cancer, coronary artery disease, and type 2 diabetes.
Beyond its diagnostic offerings, Genetic Technologies extends genetic testing services across medical, animal, forensic, and plant domains. The company also engages in strategic research and collaboration agreements with renowned institutions such as the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering Cancer Center, Cambridge University, the Ohio State University, and Shivom, enhancing its capabilities and expanding its scientific footprint in genetic research and development. Established in 1987, Genetic Technologies Limited continues to drive advancements in genetic testing technology, aiming to empower healthcare providers and individuals worldwide with personalized insights for proactive health management.
|
